Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2022
Reporting Period: Fourth Quarter and Full Year 2021
This filing serves as a notification that the Company issued an Earnings Press Release and supplemental information regarding its financial results for Q4 and full-year 2021. The actual financial data is contained in the referenced exhibits (Exhibit 99.1 and 99.2) and is not detailed within the text of this 8-K form.
Key Financial Metrics
The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are disclosed in the Earnings Press Release (Exhibit 99.1) and Supplemental Information (Exhibit 99.2) incorporated by reference.
Material Changes
No specific material changes in financial condition or operations are quantified in this filing. The document indicates that the Company announced results for the fourth quarter and full year of 2021, but the magnitude of changes versus prior periods is not stated in the provided text.
Guidance, Outlook, and Risks
- Management Commentary: The Company hosted a conference call and webcast on February 4, 2022, to discuss financial and operating initiatives.
- Non-GAAP Measures: The presentation materials (Exhibit 99.3) include non-GAAP financial information. Reconciliations to GAAP measures are available in the Supplemental Information.
- Regulatory Disclosure: The filing includes a Regulation FD disclosure regarding the presentation materials posted on the Company's website.
- Liability Disclaimer: The information in this report and its exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities thereof, except as specifically incorporated by reference in future filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q4 and full-year 2021 revenue, net income, and earnings per share figures.
- Examine Exhibit 99.2 (Supplemental Information) for reconciliations between non-GAAP and GAAP financial measures.
- Access Exhibit 99.3 (Presentation Materials) for management's outlook and discussion of operating initiatives.
- Verify the Company's liquidity position and debt maturity schedule in the full earnings release, as this 8-K does not contain these details.